Work

Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma

Year: 2015

Type: article

Abstract: PURPOSE OF REVIEW: This review will cover the role of the fibroblast growth factor pathway in the pathogenesis, targeted therapy potential and prognostic value in patients with cholangiocarcinoma (CCA). RECENT FINDINGS: Recent studies that have identified fibroblast growth factor receptor 2 (FGFR2) fusions, prognostic implications of FGFR2 fusions, treatment strategies that target FGFR2 in CCA and future directions for understanding and targeting the FGFR2 pathway in this disease, will be discussed. SUMMARY: Understanding the role of the FGFR2 pathway as a disease pathogenetic mechanism and the ability to develop targeted therapies and diagnostics surrounding this concept are critical elements toward developing novel targeted approaches in CCA.

Source: Current Opinion in Gastroenterology

DOI: 10.1097/mog.0000000000000171

Authors: Mitesh J. Borad, Gregory J. Gores, Lewis R. Roberts

Institutions: Mayo Clinic, Mayo Clinic in Arizona

Language: English

Topic: Cholangiocarcinoma and Gallbladder Cancer Studies

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Institute of Diabetes and Digestive and Kidney Diseases